MEIRAGTX HOLDINGS PLC (MGTX)

Company Profile

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 407 full-time employees. The company went IPO on 2018-06-08. The firm is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. The company has six programs in clinical development and a pipeline of preclinical and research programs. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-Linked Retinitis Pigmentosa Associated with Mutations in the RPGR Gene; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the Treatment of LCA4. The company also provides AAV-hAQP1 for the Treatment of Radiation-Induced Grade 2/3 Xerostomia, AAV-RDH12 for the Treatment of RDH12 Mutation-Associated Retinal Dystrophy, AAV-RDH12 for the Treatment of RDH12 Mutation-Associated Retinal Dystrophy and others.

Company Info

MEIRAGTX HOLDINGS PLC

450 E 29th St Fl 15

New York City NEW YORK 10016

P: 16464902965

CEO: Alexandria Forbes

Employees: 407

Website: https://meiragtx.com/